{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"10.200","floor":"9.100"},"ipodate":{"start":"2019-12-02 00:00:00","end":"2019-12-05 00:00:00"},"minimumcapital":"10302.79","subscribed":"192.10","marketcap":"91.50億","H_marketcap":"--","pe":"--","codesrate":"40.00","link":"https://staticpdf.iqdii.com/stockdata/notice/09966/2019/2019120200006_c.pdf","ipopricing":"10.200","resultdate":"2019-12-11 00:00:00","enddate":"2019-12-05 00:00:00","listeddate":"2019-12-12 00:00:00","issuenumber":"17940.30萬","issuenumberhK":"8970.20萬","issuenumberother":"8970.10萬","grayprice":"12.76","sponsors":"摩根士丹利亞洲有限公司,中信里昂證券資本市場有限公司,富瑞金融集團香港有限公司","raisemoney":"170910.00萬","use":"1、約50%（或854.6百萬港元）將用于我們的核心產品KN046的研發及商業化；\n2、約20%（或341.8百萬港元）將用于KN026的研發及商業化；\n3、約5%（或85.5百萬港元）將用于KN019的研發；\n4、約15%（或256.4百萬港元）將用于我們于蘇州的新制造及研發設施的建設；\n5、約10%（或170.9百萬港元）將用于我們的早期管線及作營運資金及一般公司用途。","shares":1000,"leadagent":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,富瑞金融集團香港有限公司,交銀國際證券有限公司,復星恒利證券有限公司,東方證券(香港)有限公司,中銀國際亞洲有限公司","bookrunners":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,富瑞金融集團香港有限公司,交銀國際證券有限公司,復星恒利證券有限公司,東方證券(香港)有限公司,中銀國際亞洲有限公司","coordinator":"摩根士丹利亞洲有限公司,中信里昂證券有限公司,富瑞金融集團香港有限公司","firstDayOpen":"13.00","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E09966","name":"康寧杰瑞制藥－Ｂ","fullname":"康寧杰瑞生物制藥"},"institutioninfo":{"principaloffice":"中國江蘇省蘇州市蘇州工業園區星湖街218號C23樓401和501室","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"徐霆","secretary":"王晉南,陳濼而","telephone":"(86512) 6285 0800","substantialshareholders":"Rubymab Ltd.(36.62%),Sky Diamond Co., Ltd.(9.56%),Pearlmed Ltd.(9.56%),PAG Growth I (BVI) Limited(5.54%),Advantech Capital II AlphaMab Partnership L.P.(5.51%)","principalactivities":"公司是一家中國領先的臨床階段生物制藥公司。","website":"http://www.alphamabonc.com/"},"managerinfo":[{"managername":"徐霆","post":"董事長、執行董事兼首席執行官","rankno":1},{"managername":"劉陽","post":"執行董事兼公司運營副總裁","rankno":2},{"managername":"許湛","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"泰康人壽保險有限責任公司","shareholding":"20,233,000.0","percentage":11.3,"ReleaseDate":"2020-06-12 00:00:00","relatedparty":"泰康保險集團股份有限公司","subsidiary":["泰康人壽保險有限責任公司"],"InverstorType":"公司"},{"institutionname":"Matthews Asia Funds","shareholding":"18,884,000.0","percentage":10.05,"ReleaseDate":"2020-06-12 00:00:00","relatedparty":"Matthews International Capital Management, LLC","subsidiary":["Matthews Asia Funds","銘基基金"],"InverstorType":"基金"},{"institutionname":"OrbiMed Funds","shareholding":"13,491,000.0","percentage":7.5,"ReleaseDate":"2020-06-12 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"Greenwoods Asset Management Limited","shareholding":"13,488,000.0","percentage":7.5,"ReleaseDate":"2020-06-12 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":49.45},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":11}